Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation

Seminars in Immunology

Volumn 22, Issue 3, 2010, Pages 125-131

  Farkas, Adam M ^a   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccine; Clinical trial; Self tolerance; Transgenic mice; Tumor antigen

Indexed keywords

BASILIXIMAB; BCG VACCINE; CANCER VACCINE; CELECOXIB; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; LIPOSOME; MUCIN 1; MUCIN 1 VACCINE; PEPTIDE VACCINE; PHOSPHORYL LIPID A; PROSTATE STEM CELL ANTIGEN; RETINOIC ACID; SB AS2; TELOMERASE; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR; AUTOANTIGEN;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; BILE DUCT CANCER; BONE MARROW CELL; BREAST CANCER; BREAST TUMOR; CANCER MODEL; CANCER SURVIVAL; CELL ACTIVITY; CLINICAL TRIAL; DENDRITIC CELL; DERMATITIS; DRUG MECHANISM; ENTEROCOLITIS; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; REVIEW; TRANSGENIC MOUSE; TUMOR; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; VITILIGO; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; FEMALE; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; MALE; METABOLISM; MOUSE; NEOPLASMS;

ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNE SYSTEM; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS;

EID: 77953621768     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2010.03.003     Document Type: Review

References (78)

1. Eyler C.E., Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008, 26:2839-2845.
2. Finn O.J. Cancer immunology. N Engl J Med 2008, 358:2704-2715.
3. Trimble C.L., Frazer I.H. Development of therapeutic HPV vaccines. Lancet Oncol 2009, 10:975-980.
4. Hislop A.D., Taylor G.S., Sauce D., Rickinson A.B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007, 25:587-617.
5. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B.J., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Immunol 2007, 178:2617-2621.
6. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
7. Jerome K.R., Barnd D.L., Bendt K.M., Boyer C.M., Taylor-Papadimitriou J., McKenzie I.F., et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991, 51:2908-2916.
8. Graziano D.F., Finn O.J. Tumor antigens and tumor antigen discovery. Cancer Treat Res 2005, 123:89-111.
9. Burnet F.M. Immunological aspects of malignant disease. Lancet 1967, 1:1171-1174.
10. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
11. Hogquist K.A., Baldwin T.A., Jameson S.C. Central tolerance: learning self-control in the thymus. Nat Rev Immunol 2005, 5:772-782.
12. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6:295-307.
13. Grossman W.J., Verbsky J.W., Barchet W., Colonna M., Atkinson J.P., Ley T.J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004, 21:589-601.
14. Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003, 4:1206-1212.
15. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
16. Lahl K., Loddenkemper C., Drouin C., Freyer J., Arnason J., Eberl G., et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 2007, 204:57-63.
17. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
18. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742.
19. Weiner H.L. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001, 182:207-214.
20. Zhou G., Drake C.G., Levitsky H.I. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006, 107:628-636.
21. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999, 59:3128-3133.
22. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623-3633.
23. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002, 3:135-142.
24. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., Engelhorn M.E., Sakaguchi S., Houghton A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004, 200:771-782.
25. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
26. Thompson R.H., Allison J.P., Kwon E.D. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 2006, 24:442-447.
27. Dejean A.S., Beisner D.R., Ch'en I.L., Kerdiles Y.M., Babour A., Arden K.C., et al. Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat Immunol 2009, 10:504-513.
28. Tivol E.A., Boyd S.D., McKeon S., Borriello F., Nickerson P., Strom T.B., et al. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997, 158:5091-5094.
29. Quezada S.A., Peggs K.S., Curran M.A., Allison J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006, 116:1935-1945.
30. van Elsas A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190:355-366.
31. van Elsas A., Sutmuller R.P., Hurwitz A.A., Ziskin J., Villasenor J., Medema J.P., et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 2001, 194:481-489.
32. Chiarella P., Massi E., De Robertis M., Signori E., Fazio V.M. Adjuvants in vaccines and for immunisation: current trends. Expert Opin Biol Ther 2007, 7:1551-1562.
33. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296.
34. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002, 99:12293-12297.
35. Marincola F.M., Jaffee E.M., Hicklin D.J., Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000, 74:181-273.
36. Danna E.A., Sinha P., Gilbert M., Clements V.K., Pulaski B.A., Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004, 64:2205-2211.
37. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
38. Gabrilovich D.I., Velders M.P., Sotomayor E.M., Kast W.M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001, 166:5398-5406.
39. Schmielau J., Finn O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001, 61:4756-4760.
40. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., et al. Gr-1+ CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006, 66:1123-1131.
41. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003, 63:4441-4449.
42. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006, 66:9299-9307.
43. Bui J.D., Schreiber R.D. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Curr Opin Immunol 2007, 19:203-208.
44. Quaglino E., Mastini C., Forni G., Cavallo F. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol 2008, Chapter 20: Unit 20 9 1- 9-10.
45. Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 230:1132-1139.
46. Ursini-Siegel J., Schade B., Cardiff R.D., Muller W.J. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007, 7:389-397.
47. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
48. Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115.
49. Chan R., Muller W.J., Siegel P.M. Oncogenic activating mutations in the neu/erbB-2 oncogene are involved in the induction of mammary tumors. Ann N Y Acad Sci 1999, 889:45-51.
50. Finkle D., Quan Z.R., Asghari V., Kloss J., Ghaboosi N., Mai E., et al. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 2004, 10:2499-2511.
51. Nanni P., Nicoletti G., De Giovanni C., Landuzzi L., Di Carlo E., Cavallo F., et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001, 194:1195-1205.
52. Quaglino E., Iezzi M., Mastini C., Amici A., Pericle F., Di Carlo E., et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004, 64:2858-2864.
53. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995, 92:3439-3443.
54. Hurwitz A.A., Foster B.A., Allison J.P., Greenberg N.M., Kwon E.D. The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol 2001, Chapter 20: Unit 20 5.
55. Nelson E.L., Prieto D., Alexander T.G., Pushko P., Lofts L.A., Rayner J.O., et al. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model. Breast Cancer Res Treat 2003, 82:169-183.
56. Garcia-Hernandez Mde L., Gray A., Hubby B., Klinger O.J., Kast W.M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008, 68:861-869.
57. Mennuni C., Ugel S., Mori F., Cipriani B., Iezzi M., Pannellini T., et al. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res 2008, 68:9865-9874.
58. Vonderheide R.H. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. Discov Med 2007, 7:103-108.
59. Vlad A.M., Kettel J.C., Alajez N.M., Carlos C.A., Finn O.J. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004, 82:249-293.
60. Peat N., Gendler S.J., Lalani N., Duhig T., Taylor-Papadimitriou J. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res 1992, 52:1954-1960.
61. Rowse G.J., Tempero R.M., VanLith M.L., Hollingsworth M.A., Gendler S.J. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 1998, 58:315-321.
62. Turner M.S., Cohen P.A., Finn O.J. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J Immunol 2007, 178:2787-2793.
63. Vlad A.M., Muller S., Cudic M., Paulsen H., Otvos L., Hanisch F.G., et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002, 196:1435-1446.
64. Ryan S.O., Vlad A.M., Islam K., Gariepy J., Finn O.J. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol Chem 2009, 390:611-618.
65. Mukherjee P., Basu G.D., Tinder T.L., Subramani D.B., Bradley J.M., Arefayene M., et al. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 2009, 182:216-224.
66. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002, 99:16168-16173.
67. Czerniecki B.J., Koski G.K., Koldovsky U., Xu S., Cohen P.A., Mick R., et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007, 67:1842-1852.
68. Palucka A.K., Ueno H., Connolly J., Kerneis-Norvell F., Blanck J.P., Johnston D.A., et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 2006, 29:545-557.
69. Bernhardt S.L., Gjertsen M.K., Trachsel S., Moller M., Eriksen J.A., Meo M., et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006, 95:1474-1482.
70. Goydos J.S., Elder E., Whiteside T.L., Finn O.J., Lotze M.T. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996, 63:298-304.
71. Ramanathan R.K., Lee K.M., McKolanis J., Hitbold E., Schraut W., Moser A.J., et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005, 54:254-264.
72. Lepisto A.J., Moser A.J., Zeh H., Lee K., Bartlett D., McKolanis J.R., et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008, 6:955-964.
73. Dreicer R., Stadler W.M., Ahmann F.R., Whiteside T., Bizouarne N., Acres B., et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 2009, 27:379-386.
74. Butts C., Murray N., Maksymiuk A., Goss G., Marshall E., Soulieres D., et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005, 23:6674-6681.
75. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003, 100:8372-8377.
76. Jacob J.B., Kong Y.C., Nalbantoglu I., Snower D.P., Wei W.Z. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J Immunol 2009, 182:5873-5881.
77. Luiten R.M., Kueter E.W., Mooi W., Gallee M.P., Rankin E.M., Gerritsen W.R., et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005, 23:8978-8991.
78. Ludewig B., Ochsenbein A.F., Odermatt B., Paulin D., Hengartner H., Zinkernagel R.M. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000, 191:795-804.